Direkt zum Inhalt springen

Closed Projects


Currently available interventional therapeutic options for the treatment of obstructive coronary artery disease comprise balloon-facilitated dilatation, followed by implantation of bare metal (BMS) or drug-eluting (DES) stents. Although these have led to a significant decrease of mortality following myocardial infarction, their long-term clinical outcomes may be limited. While BMS inherently lack sufficient efficacy to suppress neointimal growth, DES have impressively reduced this shortcoming. In consequence, in-stent restenosis could dramatically be reduced with the use of DES. However, DES are hampered by a prolonged need for potent anti-platelet therapy due to a substantial deficiency in endothelialization and biocompatibility. Therefore patients undergoing BMS or DES implantation are often in need of further revascularizations or, respectively, have to maintain long-term anti-platelet therapy, which poses them at significant bleeding risk.

In order to circumvent the limitations of current stent technologies, the aim of the current project is to render the stent surface more biocompatible. This will be achieved by influencing the migration and proliferation of vascular smooth muscle cells (VSMCs) to selectively inhibit vessel re-narrowing, and simultaneously by enhancing endothelial cell (EC) recovery of the luminal stent surface. Integrins, as extra and intracellular receptor proteins, are of great importance in cell-cell and cell-extracellular matrix interactions and are distinguishingly expressed on VSMCs and ECs (e.g avb3 and a5b1). Using RGD-peptides and peptidomimetics with high affinity and selectivity towards specific integrin receptor subtypes, we will be able to selectively target these cells and influence independently in their migrative and proliferative character. As shown schematically below (see Figure) our goal is to construct a biocompatible stent which combines i) the abluminal release of selective a5b1 ligands to suppress neointimal growth; and ii) the luminal binding of ligands selective for avb3 to the stent surface for enhanced re-endothelialization.

IGSSE setup of interdisciplinary research in project teams

Apply now: 12th call for proposals

IGSSE supports up to 10 new project teams

Call closes 2 July 2017


Apply now: IGSSE travel grant for ICCE 2017

28-29 September 2017, TU Darmstadt

Submission deadline for abstracts: 18 June 2017


IGSSE Forum 2017

29-31 May 2017, TUM Science and Study Center Raitenhaslach, Burghausen


Climate-KIC: Join the PhD Catapult

Two-week thematic summer schools across Europe


IAS Symposium: Selected topics in science and technology

8-10 May 2017, IAS Building, Garching Campus


IAS Coffee Talk with PTL Florian Praetorius

3 May 2017, 1 pm, TUM IAS Building, Garching Campus


10th IGSSE Forum

1 - 4 June 2016, TUM Science and Study Center, Burghausen


10th IGSSE Forum

Smart cooperation - science and technology in, with and for society


The Science of Cooking

Doctoral Candidates explore the Secrets of a great Dinner



Having heard of a great Canadian Kick-Off Meeting, everyone at IGSSE was thrilled to welcome the...


Breakfast at IGSSE´s

Meet the IGSSE team every other month! All the things IGSSE members wanted to asked but never dared...


Save the Date: Canadian ATUMS Speaker on "Global Science- Global Career"

26. November 2015, 6-8 pm, IAS Faculty Club, Garching Campus

20 < lib.tabbedcontent
June - 2017
Sun Mon Tue Wed Thu Fri Sat
  01 02 03
04 05 06 07 08
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 30  
Friday, 09. June 2017
Workshop: Standing up for science
9 June 2017, 9am-4pm, Brussels
Apply now: McKinsey 'Forschergeist' symposium
9-11 June 2017, Berlin For doctoral researchers and postdocs!